Impaired β-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome

American Journal of Physiology - Endocrinology and Metabolism

Volumn 287, Issue 2 50-2, 2004, Pages

  Ehrmann, David A ^a,d   Breda, Elena ^b   Corcoran, Matthew C ^a   Cavaghan, Melissa K ^a   Imperial, Jaequeline ^a   Toffolo, Gianna ^b   Cobelli, Claudio ^b   Polonsky, Kenneth S ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Insulin resistance; Insulin secretion; Type 2 diabetes

Indexed keywords

DEXAMETHASONE; GLUCOSE; INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; DEXAMETHASONE; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MATCHED-PAIR ANALYSIS; POLYCYSTIC OVARY SYNDROME; REFERENCE VALUES;

EID: 3242677155     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00475.2003     Document Type: Article

References (27)

1. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, and Ghazzi MN. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86: 1626-1632, 2001.
2. Barrett P, Bell M, Cobelli C, Golde H, Schumitzky A, Vicini P, and Foster D. SAAM II: simulation, analysis and modeling software for tracer and pharmacokinetic studies. Metabolism 47: 484-492, 1998.
3. Bergman R, Phillips L, and Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68: 1456-1467, 1981.
4. Breda E, Toffolo G, Polonsky KS, and Cobelli C. Insulin release in impaired glucose tolerance: oral minimal model predicts normal sensitivity to glucose but defective response times. Diabetes 51: S227-S233, 2002.
5. Cavaghan MK, Ehrmann DA, and Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 106: 329-333, 2000.
6. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18: 774-800, 1997.
7. Dunaif A, Segal K, Futterweit W, and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165-1174, 1989.
8. Ehrmann D, Barnes R, Rosenfield R, Cavaghan M, and Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22: 141-146, 1999.
9. Ehrmann DA, Breda E, Cavaghan MK, Bajramovic S, Imperial J, Toffolo G, Cobelli C, and Polonsky KS. Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. Diabetologia 45: 509-517, 2002.
10. Ehrmann D, Rosenfield R, Barnes R, Brigell D, and Sheikh Z. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 327: 157-162, 1992.
11. Ehrmann D, Sturis J, Byrne M, Karrison T, Rosenfield R, and Polonsky K. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 96: 520-527, 1995.
12. Faber O, Binder C, Markussen J, Heding L, Naithani V, Kuzuga H, Blix P, Horwitz D, and Rubenstein A. Characterization of seven C-peptide antisera. Diabetes 27: 170-177, 1978.
13. Fajans S and Conn J. An approach to the prediction of diabetes mellitus by modification of the glucose tolerance test with cortisone. Diabetes 3: 296-304, 1954.
14. Henriksen J, Alford F, Ward G, and Beck-Nielsen H. Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 40: 1439-1448, 1997.
15. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, and Willett WC. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345: 790-797, 2001.
16. Kahn S, Prigeon R, McCulloch D, Boyko E, Bergman R, Schwartz M, Neifing J, Ward W, Beard J, Palmer J, and Porte D. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42: 1663-1672, 1993.
17. Knochenhauer E, Key T, Kahsar-Miller M, Waggoner W, Boots L, and Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83: 3078-3082, 1998.
18. Legro R, Kunselman A, Dodson W, and Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84: 165-169, 1999.
19. Matsumoto K, Yamasaki H, Akazawa S, Sakamaki H, Ishibashi M, Abiru N, Uotani S, Matsuo H, Yamaguchi Y, Tokuyama K, and Nagataki S. High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men. J Clin Endocrinol Metab 81: 2621-2626, 1996.
20. Morgan CR and Lazarow A. Immunoassay of pancreatic and plasma insulin following alloxan injection of rats. Diabetes 14: 669-671, 1965.
21. Norman RJ, Masters L, Milner CR, Wang JX, and Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 16: 1995-1998, 2001.
22. Polonsky K, Sturis J, and Bell G. Non-insulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 334: 777-783, 1997.
23. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20: 1183-1197, 1997.
24. Sir-Petermann T, Angel B, Maliqueo M, Carvajal F, Santos JL, and Perez-Bravo F. Prevalence of type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia 45: 959-964, 2002.
25. Toffolo G, Breda E, Cavaghan MK, Ehrmann DA, Polonsky KS, and Cobelli C. Quantitative indexes of β-cell function during graded up&down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab 280: E2-E10, 2001.
26. Willi SM, Kennedy A, Wallace P, Ganaway E, Rogers NL, and Garvey WT. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin. Diabetes 51: 2895-2902, 2002.
27. Zawadzki J and Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Current Issues in Endocrinology and Metabolism. Polycystic Ovary Syndrome, edited by Dunaif A, Givens J, Haseltine F, and Merriam G. Boston, MA: Blackwell Scientific, 1992, p. 377-384.